Death · Patients with severe malaria
The fixed-effect NMR reported a difference between artesunate and quinine at every displayed average age; no GRADE assessment was reported.
2 findings from 1 review
no estimate extracted
Studies not reported
GRADE not reported
no estimate extracted
Studies not reported
GRADE not reported
Death · Patients with severe malaria
In the illustrative network meta-regression no difference in the log odds ratio for death between artesunate and artemether was seen at any displayed average age; certainty was not graded.
1 finding from 1 review
no estimate extracted
Studies not reported
GRADE not reported
Parasitological failure At 8 weeks · patients with treating urinary schistosomiasis
It is very uncertain whether artesunate changes parasitological failure At 8 weeks compared with placebo (very low certainty).
1 finding from 1 review
Mean percent egg reduction At 8 weeks · patients with treating urinary schistosomiasis
1 finding from 1 review
Microhaematuria At 8 weeks · patients with treating urinary schistosomiasis
Artesunate showed no clear difference in microhaematuria At 8 weeks compared with placebo (low certainty).
1 finding from 1 review
Adverse events · patients with treating urinary schistosomiasis
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).
1 finding from 1 review
Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) probably leads to lower total failure: day 28 (unadjusted) compared with artesunate‐amodiaquine (AS‐AQ) (moderate certainty).
2 findings from 1 review
First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).
1 finding from 1 review
Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) probably leads to lower total failure: day 28 (unadjusted) compared with mefloquine plus artesunate (MQ + AS) (moderate certainty).
2 findings from 1 review
Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).
1 finding from 1 review
First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).
1 finding from 1 review
Outcomesa · adults and children with uncomplicated P falciparum malaria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found